CL2015000572A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento. - Google Patents

Etanercept correctamente plegado de alta pureza y excelente rendimiento.

Info

Publication number
CL2015000572A1
CL2015000572A1 CL2015000572A CL2015000572A CL2015000572A1 CL 2015000572 A1 CL2015000572 A1 CL 2015000572A1 CL 2015000572 A CL2015000572 A CL 2015000572A CL 2015000572 A CL2015000572 A CL 2015000572A CL 2015000572 A1 CL2015000572 A1 CL 2015000572A1
Authority
CL
Chile
Prior art keywords
etanercept
high purity
correctly folded
preparations
folded
Prior art date
Application number
CL2015000572A
Other languages
English (en)
Inventor
Douglas Farrar
Tsutomu Arakawa
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000572(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of CL2015000572A1 publication Critical patent/CL2015000572A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

METODO DE CROMATOGRAFIA DE MODO MIXTO PARA SEPARAR LAS CONFORMACIONES CORRECTAMENTE PLEGADAS DE LAS INCORRCTAMENTE PLEGADAS DE UNA PROTEINA DADA. EL METODO ES MUY EFICAZ EN LA SEPARACIÓN DE ETANERCEPT CORRECTAMENTE PLEGADO DEL ETANERCEPT INCORRECTAMENTE PLEGADO Y DE AGREGADOS CON RENDIMIENTOS COMERCIALMENTE ATRACTIVOS QUE PERMITEN OBTENER PREPARACIONES DE ETANERCEPT DE UNA MUY ALTA PUREZA EN TÉNRMINOS DE ETANERCEPT CORRECTAMENTE PLEGADO VERSUS ETANERCEPT INCORRECTARNENTE PLEGADO. LA INVENCIÓN ESTÁ DIRIGIDA ADEMÁS A PREPARACIONES DE PROTEINAS Y FORMULACIONES QUE COMPRENDEN PROTEINAS CORRECTAMENTE PLEGADAS OBTENIDAS USANDO LOS MÉTODOS DE LA PR ESENTE, Y MÉTODOS DE TRATAMIENTO QUE EMPLEAN LAS PREPARACIONES DE GRAN PUREZA OBTENIDAS DEL METODO DE MODO MIXTO.
CL2015000572A 2012-09-11 2015-03-06 Etanercept correctamente plegado de alta pureza y excelente rendimiento. CL2015000572A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
CL2015000572A1 true CL2015000572A1 (es) 2016-02-05

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000572A CL2015000572A1 (es) 2012-09-11 2015-03-06 Etanercept correctamente plegado de alta pureza y excelente rendimiento.

Country Status (32)

Country Link
US (6) US20140072560A1 (es)
EP (1) EP2895188B1 (es)
JP (3) JP2015533797A (es)
KR (2) KR102250937B1 (es)
CN (2) CN104902914B (es)
AR (1) AR092532A1 (es)
AU (2) AU2013315750B9 (es)
BR (1) BR112015005161A2 (es)
CA (1) CA2882551A1 (es)
CL (1) CL2015000572A1 (es)
CO (1) CO7400876A2 (es)
CY (1) CY1120062T1 (es)
DK (1) DK2895188T3 (es)
DO (1) DOP2015000055A (es)
EA (1) EA031324B1 (es)
EC (1) ECSP15014138A (es)
ES (1) ES2657377T3 (es)
HR (1) HRP20180182T1 (es)
HU (1) HUE036524T2 (es)
IL (2) IL237311B (es)
IN (1) IN2015KN00452A (es)
LT (1) LT2895188T (es)
MX (2) MX360044B (es)
NO (1) NO2972131T3 (es)
PE (2) PE20200607A1 (es)
PL (1) PL2895188T3 (es)
PT (1) PT2895188T (es)
RS (1) RS57013B1 (es)
SG (1) SG11201501460RA (es)
SI (1) SI2895188T1 (es)
TW (2) TWI609877B (es)
WO (1) WO2014043103A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
TW201325606A (zh) 2011-10-18 2013-07-01 Coherus Biosciences Inc 用氯化鈉穩定化之依那西普調配物
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CA2882551A1 (en) * 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
BR112016029157A8 (pt) * 2014-06-13 2021-07-06 Lupin Ltd processo para purificar a proteína de fusão tnfr:fc
ES2733298T3 (es) * 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
RU2670166C1 (ru) * 2014-12-31 2018-10-18 ЭлДжи КЕМ, ЛТД. Способ получения слитого белка tnfr-fc с заданным содержанием примесей
EP3268042A4 (en) 2015-03-13 2018-08-01 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
CN108350027A (zh) * 2015-11-18 2018-07-31 默克专利股份公司 用于改进的蛋白质分离的相反的pH-盐梯度
WO2017084737A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
MX2018015173A (es) * 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
JP2020511516A (ja) * 2017-03-24 2020-04-16 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 組換え抗体断片の精製方法
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
CZ20032208A3 (cs) 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
ATE402716T1 (de) * 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
NZ545221A (en) 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
NZ548126A (en) * 2004-02-27 2009-10-30 Ge Healthcare Bio Sciences Ab A process for the purification of antibodies involving addition of a second resin
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
ES2436616T5 (es) 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2008045373A2 (en) 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
RU2009132986A (ru) 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
CN101778640A (zh) 2007-06-14 2010-07-14 比奥根艾迪克Ma公司 抗体制剂
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
NZ587511A (en) 2008-02-29 2012-08-31 Biogen Idec Inc Purified lymphotoxin-beta-receptor immunoglobulin fusion proteins and methods of their purification
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP2462157B1 (en) 2009-08-07 2020-06-17 EMD Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
LT2464725T (lt) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
PL2563904T3 (pl) 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
US20120264920A1 (en) * 2010-10-11 2012-10-18 Abbott Laboratories Processes for purification of proteins
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10995130B2 (en) 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
KR20140043934A (ko) * 2011-07-08 2014-04-11 머크 샤프 앤드 돔 코포레이션 Ｆｃ-융합 단백질의 정제 방법
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
TW201325606A (zh) * 2011-10-18 2013-07-01 Coherus Biosciences Inc 用氯化鈉穩定化之依那西普調配物
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP2015525762A (ja) * 2012-07-09 2015-09-07 コヒラス・バイオサイエンシズ・インコーポレイテッド エタネルセプトの安定な水性製剤
CA2882551A1 (en) * 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
CN106796355B (zh) * 2014-07-31 2020-09-22 Mtt创新公司 用于自由曲面透镜构造的数值方法：面积参数化自由曲面透镜构造
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
BR112015005161A2 (pt) 2017-07-04
ECSP15014138A (es) 2016-01-29
HUE036524T2 (hu) 2018-07-30
JP2021100929A (ja) 2021-07-08
AR092532A1 (es) 2015-04-22
US10954295B2 (en) 2021-03-23
CA2882551A1 (en) 2014-03-20
ES2657377T3 (es) 2018-03-05
TW201803593A (zh) 2018-02-01
US20190300600A1 (en) 2019-10-03
JP2015533797A (ja) 2015-11-26
EP2895188A1 (en) 2015-07-22
US11001627B2 (en) 2021-05-11
HRP20180182T1 (hr) 2018-04-20
CN104902914A (zh) 2015-09-09
IL237311A0 (en) 2015-04-30
TWI609877B (zh) 2018-01-01
MX2018012749A (es) 2020-11-12
EP2895188A4 (en) 2016-05-25
CY1120062T1 (el) 2018-12-12
LT2895188T (lt) 2018-04-10
PT2895188T (pt) 2018-02-08
CN110051823A (zh) 2019-07-26
PE20150996A1 (es) 2015-08-01
US20140072560A1 (en) 2014-03-13
CN104902914B (zh) 2019-01-01
TWI716649B (zh) 2021-01-21
US20190300601A1 (en) 2019-10-03
AU2013315750B9 (en) 2018-11-15
KR20200085937A (ko) 2020-07-15
JP6913066B2 (ja) 2021-08-04
IL267452B (en) 2021-05-31
IL237311B (en) 2019-07-31
DOP2015000055A (es) 2015-04-30
EA031324B1 (ru) 2018-12-28
US10947306B2 (en) 2021-03-16
EA201590542A1 (ru) 2015-07-30
MX360044B (es) 2018-10-19
AU2013315750B2 (en) 2018-07-12
US10954293B2 (en) 2021-03-23
RS57013B1 (sr) 2018-05-31
PE20200607A1 (es) 2020-03-10
IL267452A (en) 2019-08-29
PL2895188T3 (pl) 2018-06-29
TW201425331A (zh) 2014-07-01
MX2015003090A (es) 2015-07-14
AU2018247244B2 (en) 2020-05-28
AU2013315750A1 (en) 2015-03-05
EP2895188B1 (en) 2017-11-15
US20180037642A1 (en) 2018-02-08
AU2018247244A1 (en) 2018-11-01
US20190330325A1 (en) 2019-10-31
SI2895188T1 (en) 2018-05-31
US20190300602A1 (en) 2019-10-03
WO2014043103A1 (en) 2014-03-20
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (es) 2018-04-21
KR102133699B1 (ko) 2020-07-14
KR20150056601A (ko) 2015-05-26
US10954294B2 (en) 2021-03-23
IN2015KN00452A (es) 2015-07-17
JP2019038817A (ja) 2019-03-14
DK2895188T3 (en) 2018-02-26
SG11201501460RA (en) 2015-04-29
CO7400876A2 (es) 2015-09-30

Similar Documents

Publication Publication Date Title
CL2015000572A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento.
CY1119576T1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
CY1125436T1 (el) Αναστολεις dna-pk
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201892693A1 (ru) Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201790413A1 (ru) Антитела против tigit
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
EA201690898A1 (ru) Способы лечения таупатии
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201591379A1 (ru) Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов
EA202191122A1 (ru) СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares